Panel: Add heart failure risk to AstraZeneca, Takeda DPP-4s
This article was originally published in Scrip
Executive Summary
An FDA panel of outside experts on 14 April recommended US regulators require AstraZeneca and Takeda add new safety information to the labeling of their dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes – Onglyza (saxagliptin) and Nesina (alogliptin), respectively, and their related products.